大规模的组合选显示,抗生素耐药性格拉姆阴性ESKAPE病原体的小分子敏感化
Megan W Tse1,2, Meilin Zhu1,2, Benjamin Peters2
1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
概括
一个新的高通量查平台发现了新型抗生素组合. 一种化合物,P2-56-3,通过破坏它们的外膜,强化了对抗性细菌的里法.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 多种耐药性ESKAPE病原体的抗生素耐药性是一个关键的全球健康威胁.
- 组合抗微生物疗法提供了一种有前途的策略,用于打击耐药性和扩大抗生素谱.
- 选大型组合化学空间的协同药物组合仍然是一个重大挑战.
研究的目的:
- 部署一个高通量组合选平台,DropArray,以确定化合物和抗生素之间对ESKAPE病原体的协同相互作用.
- 发现新的小分子,增强现有抗生素对抗多药耐药细菌菌株的作用.
- 阐明已识别的协同作用药物组合的作用机制.
主要方法:
- 利用DropArray平台对超过3万种化合物进行选,对抗22种抗生素和6种克负ESKAPE病原体菌株,产生超过130万种独特的组合.
- 进行了表型分析,以验证协同作用的相互作用,并研究作用机制.
- 进行遗传查,包括CRISPR干扰 (CRISPRi),以确定药物协同作用和耐药性的遗传决定因素.
主要成果:
- 化合物与已知抗生素的协同作用比单剂活性更频繁.
- 鉴定了P2-56及其类型P2-56-3,该类型对抗抗药性Acinetobacter baumannii和Klebsiella pneumoniae的里法 (RIF) 进行了强化.
- 已经证明P2-56-3破坏了A的外膜. 宝曼尼,其与RIF的协同作用取决于脂质糖转运基因 (lpt基因).
结论:
- 通过DropArray平台,可以大规模对抗生素组合进行表型查.
- P2-56-3代表了一种有前途的化合物,可以增强利法抗多药耐药ESKAPE病原体的作用.
- 了解协同作用的遗传基础,特别是涉及外膜平衡,对于开发有效的组合疗法至关重要.
相关概念视频
Combined Effects of Drugs: Synergism
6.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.4K
Development of Antibiotic Resistance
2.0K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Mechanism of Antibiotic Resistance in MRSA
251
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
251
Inhibitors of Gram-positive Cell Wall Synthesis
225
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
225
Clinical Significance of Antibiotic Resistance
115
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
115


